logo-loader
viewZelira Therapeutics Ltd

Zelira Therapeutics fully enrols cannabis clinical trial

The clinical trial is dosing patients that have chronic non-cancer pain on long-term opioid pain relief.

Zelira Therapeutics Ltd - Zelira Therapeutics fully enrols cannabis clinical trial
The final report is expected by mid-2020

Zelira Therapeutics Ltd (ASX:ZLD) (OTCQB:ZLDAF) has now fully enrolled its Phase 1 Dose Escalation Trial in patients on long-term opioid treatment.

The trial is evaluating the safety and tolerability when dosing patients with a whole plant extract.

Secondary outcomes include pharmacokinetics and the effects on pain, mood, sleep and opioid use over the duration of the trail.

No serious adverse events from dosing patients have been reported to date.

Dosing is expected to be completed by April 2020 with the final report to be provided by mid-2020.

Trial being done with Emerald Clinics Ltd (ASX:EMD)

Zelira’s managing director Dr Richard Hopkins said: “We are delighted to have achieved full enrolment, which represents a major milestone for the trial.

“We’re also pleased for the opportunity to expand our partnership with Emerald Clinics by bringing them on as a second site.

“We have been impressed by their ability to complement the efforts of the St Vincent team by rapidly screening and enrolling eligible patients into trial.”

Recent placement secures $4.6 million

Zelira recently accepted applications from overseas investors for an additional 1.08 million shares as part of a share placement.

Following the acceptance of oversubscriptions, the placement’s total size increased to $4.64 million.

The funds will be used to accelerate Zelira’s plans to launch multiple products into global markets in 2020 and to advance its clinical programs, including its Insomnia and Opioid Sparing trials, which are due to read-out in the first half of this year.

A global therapeutic medicinal cannabis company

Zelira is a leading global therapeutic medicinal cannabis company with access to the world’s largest and fastest-growing cannabis markets.

The company owns a portfolio of proprietary revenue-generating products and a pipeline of candidates undergoing clinical development that are positioned to enter global markets from 2020.

It is currently undertaking:

  • Human clinical trial programs focused on insomnia, autism and opioid reduction with activities in Australia and the USA; and
  • Pre-clinical research examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

Quick facts: Zelira Therapeutics Ltd

Price: 0.032 AUD

ASX:ZLD
Market: ASX
Market Cap: $30.92 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Zelira Therapeutics Ltd named herein, including the promotion by the Company of Zelira Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Zelira Therapeutics releases interim data for Phase II...

Zelira Therapeutics Ltd (ASX:ZLD) managing director Dr Richard Hopkins, chairman Osagie Imasogie and clinical trial principal investigator Professor Peter Eastwood, of the University of Western Australia, update Proactive on results from the company’s Phase II clinical trial of medicinal...

on 02/21/2020

2 min read